Skip to main content

Table 2 Association of promoter methylation with clinic pathologic characteristics of CRC patients (N = 307)

From: DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

CharacteristicsTotalSFRP1 N (%)SFRP2 N (%)WIF1 N (%)
NHypo-M aHyper-M bP valueHypo-MHyper-MP valueHypo-MHyper-MP value
All cases30755 (17.9)252 (82.1) 264 (86.0)43 (14.0) 224 (73.3)83 (26.7) 
Age   0.040  0.382  0.459
  < 45 years-old337 (12.7)26 (10.3) 26 (9.8)7 (16.3) 27 (12.1)6 (7.2) 
 45~60 years-old13231 (56.4)101 (40.1) 113 (42.8)19 (44.2) 96 (42.9)36 (43.4) 
  ≥ 60 years-old14217 (30.9)125 (49.6) 125 (47.4)17 (39.5) 101 (45.0)41 (49.4) 
Gender   0.766  0.944  0.224
 Male18033 (60.0)147 (58.3) 155 (58.7)25 (58.1) 136 (60.7)44 (53.0) 
 Female12722 (40.0)105 (41.7) 109 (41.4)18 (41.9) 88 (39.3)39 (47.0) 
CEA   0.930  0.207  0.824
  < 5 ng/mL13023 (41.8)107 (42.5) 108 (40.9)22 (51.2) 94 (42.0)36 (43.4) 
  ≥ 5 ng/mL17732 (58.2)145 (57.5) 156 (59.1)21 (48.8) 130 (58.0)47 (56.6) 
CA19–9   0.114  0.180  0.327
  < 37 U/mL23237 (67.3)195 (77.4) 196 (74.2)36 (83.7) 166 (74.1)66 (79.5) 
  ≥ 37 U/mL7518 (32.7)57 (22.6) 68 (25.8)7 (16.3) 58 (25.9)17 (20.5) 
Multiple polyps   0.600  0.127  0.115
 No22041 (74.5)179 (71.0) 185 (70.1)35 (81.4) 155 (69.2)65 (78.3) 
 Yes8714 (25.5)73 (29.0) 79 (29.9)8 (18.6) 69 (30.8)18 (21.7) 
Tumor location   0.424  0.326  0.809
 Colon11518 (32.7)97 (38.5) 96 (36.4)19 (44.2) 83 (37.1)32 (38.6) 
 Rectum19237 (67.3)155 (61.5) 168 (63.6)24 (55.8) 141 (62.9)51 (61.4) 
TNM Staging   0.121  0.042  0.311
 I- II16324 (43.6)139 (55.2) 134 (50.8)29 (67.4) 115 (51.3)48 (57.8) 
 III-IV14431 (56.4)113 (44.8) 130 (49.2)14 (32.6) 109 (48.7)35 (42.2) 
Tumor invasion   0.364  0.111  0.183
 T1- T315124 (42.9)127 (50.4) 125 (47.3)26 (60.5) 105 (46.9)46 (55.4) 
 T415631 (56.4)125 (49.6) 139 (52.7)17 (39.5) 119 (53.1)37 (44.6) 
Lymph nodes involved   0.036  0.056  0.403
 N017324 (43.6)149 (59.1) 143 (54.2)30 (69.8) 123 (54.9)50 (60.2) 
 N1- N213431 (56.4)103 (40.9) 121 (45.8)13 (30.2) 101 (45.1)33 (39.8) 
Metastasis status   0.231  0.165  0.384
 M028453 (96.4)231 (91.7) 242 (91.7)42 (97.7) 209 (93.3)75 (90.4) 
 M1232 (3.6)21 (8.3) 22 (8.3)1 (2.3) 15 (6.7)8 (9.6) 
Pathological classification   0.053  0.316  0.023
 Prominence19931 (56.4)168 (66.7) 168 (63.6)31 (72.1) 135 (60.3)64 (77.1) 
 Ulceration8616 (29.1)70 (27.8) 78 (29.5)8 (18.6) 71 (31.7)15 (18.1) 
 Others228 (14.5)14 (5.5) 18 (6.9)4 (9.3) 18 (8.0)4 (4.8) 
Histologic classification   0.044  0.113  0.361
 Adenocarcinoma23535 (63.6)200 (79.4) 203 (76.9)32 (74.4) 176 (78.6)59 (71.1) 
 Mucinous adenocarcinoma6819 (34.5)49 (19.4) 59 (22.3)9 (20.9) 45 (20.1)23 (27.7) 
 Others41 (1.9)3 (1.2) 2 (0.8)2 (4.7) 3 (1.3)1 (1.2) 
Differentiation degree   0.011  0.083  0.255
 Poor4915 (27.3)34 (13.5) 46 (17.4)3 (7.0) 39 (17.4)10 (12.0) 
 Moderate or well25840 (72.7)218 (86.5) 218 (82.6)40 (93.0) 185 (82.6)73 (88.0) 
  1. aHypomethylation
  2. bHypermethylation